MapLight Therapeutics (MPLT) Corporate presentation summary

Strategic vision and discovery platform

• Focus on improving outcomes for patients with CNS disorders using a circuit-driven discovery engine and diversified pipeline.

• Platform identifies and validates novel drug targets causally linked to disease symptoms.

• Led by experts in neuropsychiatry, leveraging deep circuit biology and medicinal chemistry expertise.

• Strong financial position with ~$450M in cash and runway through 2027.

Pipeline and clinical development

• Advancing a broad pipeline targeting schizophrenia, Alzheimer's disease psychosis (ADP), autism spectrum disorder (ASD), and other neuropsychiatric disorders.

• Lead asset ML-007C-MA is a novel M₁/M4 muscarinic agonist in combination with a peripheral antagonist, in Phase 2 for schizophrenia and ADP.

• ML-004 (zolmitriptan formulation) in Phase 2 for ASD sociability and irritability symptoms.

• Additional preclinical programs in hyperactivity, impulsivity, and Parkinson's disease.

Differentiation and clinical rationale

• ML-007C-MA designed for robust M₁/M4 activation with synchronized peripheral antagonist exposure, aiming for improved safety, tolerability, and ease of use.

• Demonstrated strong in vitro and in vivo activity, with potential for comprehensive symptom improvement across positive, negative, and cognitive domains.

• Phase 1 studies showed mostly mild and transient adverse events, low rates of vomiting and anticholinergic effects, and no severe or serious events.

• Dosing is convenient (QD/BID), with minimal titration and no fasting requirements.